Takami Sato, MD, Ph.D
Philadelphia, PA 19107
Research and Clinical Interests
Medical Oncology, Melanoma, Skin Cancer, Uveal Melanoma, Ocular Melanoma, Cancer Immunotherapy
As director of the Metastatic Uveal Melanoma Program at Jefferson, Dr. Sato heads one of the few programs in the United States treating melanoma originating in the eye. Although uveal melanoma is the most common adult eye tumor, the disease is very rare, affecting only six or seven people per one million. This cancer commonly spreads to the liver, and patients who do not receive treatment live an average of six months. Dr. Sato has devoted his career to improving understanding of this disease and developing new treatments, particularly for patients who are not eligible for surgery.
Dr. Sato’s studies focus on cancer immunotherapy, or the use of the immune system to fight cancer. His clinical trials involving a procedure called immunoembolization have shown promising results.
In immunoembolization, a chemical to stimulate patients’ immune systems is administered to the hepatic artery that feeds the liver tumor and then the artery is blocked, cutting off oxygen to tumors and keeping the injected medicine in the tumor. In one trial, one-third of patients had tumor shrinkage, and another third experienced no tumor growth. Dr. Sato is building on these outcomes as he continues to examine methods of treating uveal melanoma and delaying its progression.
Most Recent Peer-Reviewed Publications
- A Comprehensive Patient-Derived Xenograft Collection Representing the Heterogeneity of Melanoma
- Phase 1 Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for Melanoma Patients With Brain Metastases
- Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis
- Co-Targeting HGF/cMET Signaling with MEK Inhibitors in metastatic uveal melanoma
- Relationship between physician-adjudicated adverse events and patient-reported health-related quality of life in a phase II clinical trial (NCT01143402) of patients with metastatic uveal melanoma
- Adjuvant Sunitinib in High-Risk Patients with Uveal Melanoma. Comparison with Institutional Controls
- Ladarixin, a dual CXCR1/2 inhibitor, attenuates experimental melanomas harboring different molecular defects by affecting malignant cells and tumor microenvironment
- Immune check point inhibitors combination in melanoma: Worth the toxicity?
- Establishment and Characterization of Orthotopic Mouse Models for Human Uveal Melanoma Hepatic Colonization
- Yttrium-90 microsphere brachytherapy for liver metastases from uveal melanoma clinical outcomes and the predictive value of fluorodeoxyglucose positron emission tomography
- Arterial Blood, Rather Than Venous Blood, is a Better Source for Circulating Melanoma Cells
- Paracrine effect of NRG1 and HGF drives resistance to MEK inhibitors in metastatic uveal melanoma
- Biology of advanced uveal melanoma and next steps for clinical therapeutics
- Double-blinded, randomized phase II study using embolization with or without granulocyte-macrophage colony-stimulating factor in uveal melanoma with hepatic metastases
- Treatment strategies for clinically detectable metastatic uveal melanoma
- Expression of insulin-like growth factor-1 receptor in metastatic uveal melanoma and implications for potential autocrine and paracrine tumor cell growth
- Tumor necrosis factor-α blockade and development of uveal melanoma: Expected adverse effect or just coincidence?
- Integrin receptors on tumor cells facilitate NK cell-mediated antibody-dependent cytotoxicity
- High-dose vincristine sulfate liposome injection (Marqibo) is not associated with clinically meaningful hematologic toxicity
- Early arterial stasis during resin-based yttrium-90 radioembolization: Incidence and preliminary outcomes